Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: The RODIN study

Blood

Volumn 121, Issue 20, 2013, Pages 4046-4055

  Gouw, Samantha C ^a   Van Den Berg, H Marijke ^b   Fischer, Kathelijn ^b,c   Auerswald, Gunter ^d   Carcao, Manuel ^e   Chalmers, Elizabeth ^f   Chambost, Herve ^g   Kurnik, Karin ^h   Liesner, Ri ⁱ   Petrini, Pia ^j   Platokouki, Helen ^k   Altisent, Carmen ^l   Oldenburg, Johannes ^m   Nolan, Beatrice ⁿ   Garrido, Rosario Perez ^o   Mancuso, M Elisa ^p   Rafowicz, Anne ^q   Williams, Mike ^r   Clausen, Niels ^s   Middelburg, Rutger A ^t   Ljung, Rolf ^u   Van Der Bom, Johanna G ^t,v   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d KLINIKUM BREMEN MITTE   (Germany)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^g AIX MARSEILLE UNIVERSITY   (France)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k Haemophilia Haemostasis Unit   (Greece)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m UNIVERSITY HOSPITAL BONN   (Germany)

ⁿ ST JAMES S HOSPITAL   (Ireland)

^o HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^p FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^q Centre de Traitement de la Douleur   (France)

^r BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^s AARHUS UNIVERSITY HOSPITAL   (Denmark)

^t Center for Clinical Transfusion Research   (Netherlands)

^u LUND UNIVERSITY HOSPITAL   (Sweden)

^v LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING INHIBITOR;

ADULT; ARTICLE; BLEEDING; COHORT ANALYSIS; DRUG EXPOSURE; DRUG MEGADOSE; GENOTYPE; HEMOPHILIA A; HUMAN; INDEL MUTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY ANALYSIS; ADOLESCENT; BLOOD; CHEMOPROPHYLAXIS; CHILD; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; MULTICENTER STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHEMOPREVENTION; CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

MLCS; MLOWN;

EID: 84881014770     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-457036     Document Type: Article

References (32)

1. Donadel-Claeyssens S; European Paediatric Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia. 2006;12(2):124-127.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418-435.
4. Leissinger C, Cooper DL, Solem CT; HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. Haemophilia. 2011;17(6): 884-889.
5. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74(6): 1402-1406.
6. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12): 2922-2934.
7. Astermark J, Berntorp E, White GC, Kroner BL; MIBS Study Group. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7(3):267-272.
8. Hay CR, Ollier W, Pepper L, et al. UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost. 1997;77(2):234-237.
9. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77(2):238-242.
10. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107(8):3167-3172.
11. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006;108(12):3739-3745.
12. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost. 2007;5(2):263-265.
13. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia. 2011;17(4): 641-649.
14. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009;7(12):2006-2015.
15. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
16. Pfistershammer K, Stockl J, Siekmann J, Turecek PL, Schwarz HP, Reipert BM. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost. 2006;96(3):309-316.
17. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol. 2007;136(1):12-25.
18. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648-4654.
19. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5(7): 1383-1390.
20. Maclean PS, Richards M, Williams M, et al; Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia. 2011;17(2):282-287.
21. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005;130(3): 422-427.
22. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16(2):256-262.
23. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients-long-term followup and continuing experience. Haemophilia. 2012;18(1):e18-e20.
24. Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost. 1993;69(1):87.
25. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
26. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990;9(12):1501-1515.
27. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
28. Lefebvre G, Delaney JA, Platt RW. Impact of misspecification of the treatment model on estimates from a marginal structural model. Stat Med. 2008; 27(18):3629-3642.
29. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664.
30. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol. 1991;13(3):280-287.
31. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002;99(7):2337-2341.
32. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73(5):691-701.